JNP Medi Advances AI-Based Clinical Solution Development for Geriatric Brain Diseases

J&P Medi announced on the 17th that it has signed a business agreement with the Research Institute of Dementia (RID) to develop AI-based clinical solutions. The signing ceremony was attended by J&P Medi CEO Jeong Kwon-ho, Gwangju Dementia Cohort Research Center Director Lee Geon-ho, and key executives from both sides. Through this agreement, the two organizations will focus on combining data and technological capabilities to advance the clinical trial management system and maximize success rates and operational efficiency.

Lee Geon-ho, Director of the Gwangju Dementia Cohort Research Center (left), and Jung Kwon-ho, CEO of J&P Medi, are posing for a commemorative photo at the signing ceremony for a business cooperation agreement to develop AI-based clinical solutions.
[Photo by J&P Medi]

The core of this collaboration is to integrate J&P Medi’s clinical operation experience and AI development capabilities with RID’s clinical trial preparation cohort to develop a high-speed digital clinical validation and regulatory clinical platform. This aims to quickly and accurately select suitable clinical subjects, predict dropout possibilities in advance, and enhance the efficiency of patient management systems to maximize the success rate of clinical trials. Additionally, the two organizations plan to jointly develop AI solutions capable of analyzing and predicting geriatric brain diseases based on comprehensive clinical data such as cognitive function tests, metabolic information, imaging, and genomics. Through this, they aim to maximize data utilization throughout all clinical trial processes and lay the foundation for clinical research to overcome geriatric brain diseases.

Jeong Kwon-ho, CEO of J&P Medi, stated, “This agreement will be an important opportunity to accelerate the digital transformation and AI innovation of clinical trials,” adding, “By combining the strengths of both institutions, we expect to enhance competitiveness in the global market and further contribute to improving patients’ quality of life.”